Built to Exit: Due Diligence in Private-Equity Backed Life Science Deals

Key Takeaways

• The strategies that drove private equity in life sciences have shifted from straightforward to something more deliberate.
• The organizations winning in this new environment are not necessarily the ones sourcing deals the fastest. They are the ones treating diligence as a discipline of comprehensive workstreams and enterprise value allocation that starts at the first conversation and continues through the day a sponsor plans its longer-term exit
• Dealmaking discipline in life sciences private equity is not a single phase of a transaction. It is a continuous thread that runs from the first diligence conversation through the hold period and into the eventual exit, and the sponsors and management teams that treat it that way tend to see fewer surprises and better outcomes at every stage.

How Private Equity Investment in Life Sciences Is Changing

For several years, the dominant private equity strategy in life sciences was straightforward: acquire quickly, acquire often, and build scale through volume. Platforms grew by addition, and the winning sponsors were often the ones who moved fastest.

That approach is giving way to something more deliberate. Sponsors are doing fewer deals, underwriting each one more rigorously, and looking for value they can point to in the near term rather than a story that pays off years down the road. Private equity firms are focused on revenue-generating life science services, labs, and medical device/equipment transactions that are less dependent on breakthrough research and development investment. Private equity firms are also reallocating purchase prices to offer less cash upfront at closing, require selling shareholders to roll over equity, and assign a larger percentage of enterprise value to future financial, operating, and technology milestones.

Organizations that would need a heavy lift to fix their science, navigate the FDA regulatory approval process, or commercialize new technology into approved, revenue-generating products are having a harder time finding a private equity buyer or investor than they once did. Capital is readily available, but far more discriminatory and difficult to access. Additionally, the private equity approval committees that decide where investment funds are allocated are asking tougher questions and requiring far more in-depth financial, technology, commercial, and operational due diligence, as well as sustainability assessments, before they sign off and invest in life science companies.

The organizations winning in this environment are not necessarily the ones sourcing deals the fastest. They are the ones treating diligence as a discipline of comprehensive workstreams and enterprise value allocation that starts at the first conversation and continues through the day a sponsor plans its longer-term exit.

This shift changes what "deal-ready" means for management teams, and it changes what disciplined diligence looks like for the sponsors underwriting them. That is where our Transaction Advisory Services (TAS) team spends most of its time, and where the practical lessons in this article come from.

What Makes a Life Sciences Company Diligence-Ready?

Before a term sheet is drafted, sponsors are already assessing whether a life sciences company is prepared for outside capital. Companies that move efficiently through diligence typically demonstrate readiness in three areas:

Reliable financial information with a clear underlying story. Financial records should consistently document revenue recognition, customer concentration, margin trends, and other key performance measures in a manner reasonably consistent with US GAAP. Sponsors need to understand not only what the numbers show, but also what is driving them and how revenue, margin, contribution, and EBITDA may support future enterprise value.

A defensible regulatory and intellectual property position. Unresolved regulatory issues or poorly documented intellectual property protections can delay or derail a life sciences transaction, regardless of the strength of the underlying business.

A management team with command of the business. Leaders should be able to explain the company’s cost structure, R&D and regulatory processes, key-person dependencies, and operating priorities. That command gives sponsors confidence that the organization can withstand the scrutiny that follows a signed letter of intent.

Beyond these core attributes, early process signals can indicate whether a transaction is likely to progress to an executed letter of intent. Sponsors should look for the following:

• The board has aligned on essential deal principles—including the price floor, retained rights, and acceptable structures—before a term sheet is drafted.
• One designated leader has clear authority to manage the negotiation and coordinate the company’s response.
• The company has conducted its own sell-side diligence and proactively disclosed known financial, technological, and operational strengths and weaknesses.
• Management understands and is prepared to address timing pressures, such as a limited cash runway, recent pipeline results, or a competitive bidding process.
• Core diligence materials—including quality of earnings analyses, financial audits, technology and IP validation, and financial projections—are current, readily available, and supported by primary-source data.

How Private Equity Due Diligence Has Evolved

Private equity diligence now goes beyond confirming historical results. Sponsors are testing whether earnings are sustainable, forecasts are credible, and the investment thesis can be executed after close. That shift is showing up in six key areas:

• Greater emphasis on revenue and earnings quality and resilience. As the market moves away from cheap-capital multiple expansion, buyers are placing more weight on operational performance, sustainable and quantifiable revenue streams, defensible earnings, margin durability, and downside risk—not simply whether historical results are accurate.
• A broader role for quality of earnings analyses. Quality of earnings reports remain a standard and foundational part of private equity transactions, but their purpose has expanded beyond validating adjusted EBITDA. Sponsors also use them to evaluate customer behavior, price-volume-mix, margin durability, and the company’s ability to act on those findings after close.
• Earlier scrutiny of working capital, purchase price adjustments, and integration. Diligence increasingly identifies net working capital targets, debt-like items, and potential integration costs or opportunities before close. Sponsors also expect a defined integration playbook, 100-day plan, and accountable team; the absence of that planning can be a red flag and a major factor to enterprise value leakage post-close.
• More rigorous testing of the investment thesis. A defensible EBITDA adjustment does not establish that the investment plan is achievable. Diligence must also determine whether management can track the relevant KPIs, implement the identified improvements, and deliver the expected value after close.
• Closer examination of forecasts and downside scenarios. Sponsors are weighing revenue and earnings resilience and forecast credibility more heavily than headline growth alone. Assumptions must be supportable under both the base case and plausible downside scenarios.
• More attention to cash conversion and revenue durability. Buyers are closely examining the gap between normalized EBITDA and cash flow, customer concentration, recurring or annuity-based revenue, capex investment, and whether revenue recognition policies are consistently applied in accordance with US GAAP.

Building Exit Readiness Throughout the Hold Period

Sellers who start the sell-side preparation 1-2 years in advance of a PE exit will experience significantly improved valuations and successful transaction close timelines. Sellers that delay developing a sell-side plan within 6 months of transaction execution experienced more rigorous buy-side due diligence, timeline delays, and larger disallowance rates to normalized EBITDA adjustments.

Additionally, the most successful transactions were synonymous with companies that had built and continuously maintained robust value creation systems and EBITDA reporting trackers years in advance of a potential exit, rather than being constructed at the point in time when a transaction was being negotiated.

Sellers that have identified key components of normalized EBITDA and have established well-defined initiatives and project owners to manage and maximize such EBITDA components on a monthly or quarterly basis, years in advance of an actual transaction, will generally fare much better in terms of negotiated enterprise value, timeline execution, and reduced barriers to successful closing.

It is also important for a seller to develop a robust data room well in advance of entering a sell-side process. Companies that assigned responsibility to an experienced senior executive or professional advisor to develop, maintain, and quality-control the Data Room on a continuous basis with relevant financial, human resource, legal contracts, and operational (customer, product, facilities, etc.) data, which has been vetted by professional advisors, have resulted in improved negotiation results and successful deal closings.

Preparing for a Private Equity Exit

A well-run exit is, in many respects, diligence conducted in advance and controlled by the seller rather than after the fact by the buyer. The organizations that move through a sale process with the fewest delays are usually the ones that have already asked themselves the questions a buyer's team will ask and have already assembled the answers.

For management teams anticipating a future transaction, whether that is 12 months away or three years away, a short readiness checklist can prevent the kind of last-minute scramble that erodes both timeline and value. That checklist should include:

• Is our data room current, or would it take weeks to assemble from scratch?
• Can we explain every meaningful swing in our financial performance over the past two years, not just the trend line?
• Are our regulatory and intellectual property records complete and organized in one place?
• Do we have a documented view of our own key person dependencies, and a plan to address them?

None of these questions requires a live deal process to answer. The organizations that answer them early tend to move through their eventual sale with more control over price, terms, and timeline.

Treating Due Diligence as a Continuous Discipline

Dealmaking discipline in life sciences private equity is not a single phase of a transaction. It is a core competency and continuous thread that runs from the first diligence conversation through the hold period and into the eventual exit, and the sponsors and management teams that treat it that way tend to see fewer surprises and better outcomes at every stage.

At EisnerAmper, our Transaction Advisory Services team works with private equity and family office sponsors and management teams at each point along that thread, from initial screening through exit preparation. If your organization is evaluating a transaction or preparing for one down the road, we welcome the conversation.